Literature DB >> 22992238

Management of joint bleeding in hemophilia.

Mindy L Simpson1, Leonard A Valentino.   

Abstract

Hemarthrosis, the hallmark of severe hemophilia, is the major cause of serious bleeding events, disability and reduced quality of life in patients with factor VIII or factor IX deficiency. Joint bleeding is one of the greatest challenges confronting individuals treating hemophilia, and its economic impact is enormous. This article reviews the current management of hemophilic joint bleeding and discusses the potential impact of novel therapies.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22992238     DOI： 10.1586/ehm.12.27

Source DB:  PubMed          Journal:  Expert Rev Hematol        ISSN： 1747-4094            Impact factor:   2.929


  14 in total

1.  Novel Piperazino-Enaminones Decrease Pro-inflammatory Cytokines Following Hemarthrosis in a Hemophilia Mouse Model.

Authors:  Chen Zhong; Doreen Szollosi; Junjiang Sun; Baolai Hua; Ola Ghoneim; Ashley Bill; Yingping Zhuang; Ivan Edafiogho
Journal:  Inflammation       Date:  2019-10       Impact factor: 4.092

Review 2.  Low Dose Prophylaxis in Hemophilia Care.

Authors:  Neeraj Sidharthan; Remya Sudevan
Journal:  Indian J Hematol Blood Transfus       Date:  2019-06-15       Impact factor: 0.900

3.  Health care resource utilization and cost burden of hemophilia B in the United States.

Authors:  Tyler W Buckner; Iryna Bocharova; Kaitlin Hagan; Arielle G Bensimon; Hongbo Yang; Eric Q Wu; Eileen K Sawyer; Nanxin Li
Journal:  Blood Adv       Date:  2021-04-13

4.  Selective inhibition of activated protein C anticoagulant activity protects against hemophilic arthropathy in mice.

Authors:  Jhansi Magisetty; Vijay Kondreddy; Shiva Keshava; Kaushik Das; Charles T Esmon; Usha R Pendurthi; L Vijaya Mohan Rao
Journal:  Blood       Date:  2022-05-05       Impact factor: 25.476

Review 5.  A Review of Current Management of Knee Hemarthrosis in the Non-Hemophilic Population.

Authors:  Nikhil Potpally; Scott Rodeo; Paul So; Ken Mautner; Michael Baria; Gerard A Malanga
Journal:  Cartilage       Date:  2020-07-22       Impact factor: 3.117

6.  EPCR deficiency or function-blocking antibody protects against joint bleeding-induced pathology in hemophilia mice.

Authors:  Jhansi Magisetty; Usha R Pendurthi; Charles T Esmon; L Vijaya Mohan Rao
Journal:  Blood       Date:  2020-06-18       Impact factor: 22.113

7.  Blood-induced bone loss in murine hemophilic arthropathy is prevented by blocking the iRhom2/ADAM17/TNF-α pathway.

Authors:  Coline Haxaire; Narine Hakobyan; Tania Pannellini; Camila Carballo; David McIlwain; Tak W Mak; Scott Rodeo; Suchitra Acharya; Daniel Li; Jackie Szymonifka; Xiangqian Song; Sébastien Monette; Alok Srivastava; Jane E Salmon; Carl P Blobel
Journal:  Blood       Date:  2018-05-18       Impact factor: 22.113

Review 8.  Haemophilia.

Authors:  Erik Berntorp; Kathelijn Fischer; Daniel P Hart; Maria Elisa Mancuso; David Stephensen; Amy D Shapiro; Victor Blanchette
Journal:  Nat Rev Dis Primers       Date:  2021-06-24       Impact factor: 52.329

Review 9.  Hemophilic arthropathy in a patient with multi-joint replacement: A case report and literature review.

Authors:  Wei Zhu; Xuxia He; Zenan Xia; Jiliang Zhai; Xisheng Weng
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

Review 10.  Evaluation and Management of Septic Arthritis and its Mimics in the Emergency Department.

Authors:  Brit Long; Alex Koyfman; Michael Gottlieb
Journal:  West J Emerg Med       Date:  2018-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.